ASH 2021: Lisocabtagene Maraleucel Beats Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Benefits were observed despite high degree of crossover to the experimental arm
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.